Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 8/20 | 0.53 |
| ▸ | CSF1R | P07333 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 5/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046656 | 0.93 | SYK (0.66) | SYKDDR2BRAFABL1TEK | |
| SCHEMBL10043994 | 0.89 | SYK (0.62) | SYKDDR2DDR1BRAFCSF1R | |
| SCHEMBL5046414 | 0.88 | SYK (0.65) | SYKDDR2BRAFABL1TEK | |
| SCHEMBL14011549 | 0.88 | SYK (0.61) | SYKDDR2BRAFABL1TEK | |
| SCHEMBL14011563 | 0.87 | SYK (0.63) | SYKDDR2BRAFABL1TEK | |
| SCHEMBL14011530 | 0.86 | SYK (0.61) | SYKDDR2BRAFABL1TEK | |
| SCHEMBL14011539 | 0.86 | SYK (0.68) | SYKDDR2BRAFABL1TEK | |
| SCHEMBL14011551 | 0.86 | SYK (0.66) | SYKDDR2BRAFCSF1RABL1 | |
| SCHEMBL14011533 | 0.85 | SYK (0.61) | SYKDDR2BRAFABL1TEK | |
| SCHEMBL14011558 | 0.84 | SYK (0.65) | SYKDDR2BRAFABL1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1863774-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2010-12-15 | — | — | CN | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| CN-1863774-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-11-15 | — | — | CN | disclosed |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | FYN, LCK, SRC | SYK 30/4885DDR2 452/4885DDR1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.